508 related articles for article (PubMed ID: 28825374)
1. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
2. Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know.
Filetti M; Giusti R; Di Napoli A; Iacono D; Marchetti P
Tumori; 2019 Dec; 105(6):NP48-NP51. PubMed ID: 31221037
[TBL] [Abstract][Full Text] [Related]
3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
4. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
[No Abstract] [Full Text] [Related]
5. Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report.
Kartal Ö; Ataş E
Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30404191
[TBL] [Abstract][Full Text] [Related]
6. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
7. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
9. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
10. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Cooper DS; Meriggioli MN; Bonomi PD; Malik R
J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
[TBL] [Abstract][Full Text] [Related]
11. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
12. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
13. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
[TBL] [Abstract][Full Text] [Related]
14. Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review.
Meri-Abad M; Cunquero Tomás AJ; Jaime AB
Melanoma Res; 2021 Apr; 31(2):186-189. PubMed ID: 33625098
[TBL] [Abstract][Full Text] [Related]
15. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
16. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
17. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
[TBL] [Abstract][Full Text] [Related]
19. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
Roth P; Valavanis A; Weller M
Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
[No Abstract] [Full Text] [Related]
20. Hyperprogression after nivolumab for melanoma: A case report.
Yilmaz M; Akovali B
J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
